Arcellx (ACLX) Competitors $69.75 +0.36 (+0.52%) Closing price 04:00 PM EasternExtended Trading$69.76 +0.01 (+0.01%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACLX vs. VTRS, RDY, ASND, QGEN, MRNA, BBIO, ELAN, VRNA, ROIV, and GRFSShould you be buying Arcellx stock or one of its competitors? The main competitors of Arcellx include Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), QIAGEN (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Arcellx vs. Its Competitors Viatris Dr. Reddy's Laboratories Ascendis Pharma A/S QIAGEN Moderna BridgeBio Pharma Elanco Animal Health Verona Pharma PLC American Depositary Share Roivant Sciences Grifols Viatris (NASDAQ:VTRS) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends. Does the media prefer VTRS or ACLX? In the previous week, Arcellx had 10 more articles in the media than Viatris. MarketBeat recorded 12 mentions for Arcellx and 2 mentions for Viatris. Arcellx's average media sentiment score of 1.61 beat Viatris' score of 0.05 indicating that Arcellx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Arcellx 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts prefer VTRS or ACLX? Viatris currently has a consensus price target of $10.40, indicating a potential downside of 1.52%. Arcellx has a consensus price target of $114.31, indicating a potential upside of 63.88%. Given Arcellx's stronger consensus rating and higher possible upside, analysts plainly believe Arcellx is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80Arcellx 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.13 Which has more volatility and risk, VTRS or ACLX? Viatris has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Do insiders & institutionals believe in VTRS or ACLX? 79.9% of Viatris shares are held by institutional investors. Comparatively, 96.0% of Arcellx shares are held by institutional investors. 0.1% of Viatris shares are held by company insiders. Comparatively, 8.4% of Arcellx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is VTRS or ACLX more profitable? Viatris has a net margin of -24.57% compared to Arcellx's net margin of -329.93%. Viatris' return on equity of 16.54% beat Arcellx's return on equity.Company Net Margins Return on Equity Return on Assets Viatris-24.57% 16.54% 7.06% Arcellx -329.93%-43.04%-27.41% Which has higher earnings and valuation, VTRS or ACLX? Arcellx has lower revenue, but higher earnings than Viatris. Arcellx is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViatris$14.74B0.84-$634.20M-$2.90-3.64Arcellx$107.94M35.84-$107.35M-$3.42-20.39 SummaryArcellx beats Viatris on 10 of the 17 factors compared between the two stocks. Get Arcellx News Delivered to You Automatically Sign up to receive the latest news and ratings for ACLX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACLX vs. The Competition Export to ExcelMetricArcellxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.85B$3.12B$5.75B$9.77BDividend YieldN/A2.28%6.66%4.50%P/E Ratio-20.3920.8682.5826.38Price / Sales35.84396.75535.42110.55Price / CashN/A43.5325.7028.92Price / Book9.878.1011.196.58Net Income-$107.35M-$53.35M$3.28B$265.84M7 Day Performance-0.21%-0.14%0.15%-0.07%1 Month Performance-1.95%9.18%8.34%5.83%1 Year Performance1.47%7.53%54.21%17.88% Arcellx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACLXArcellx2.1476 of 5 stars$69.75+0.5%$114.31+63.9%+0.9%$3.85B$107.94M-20.3980News CoveragePositive NewsGap DownVTRSViatris2.6661 of 5 stars$10.55-0.9%$10.40-1.4%-12.7%$12.42B$14.12B-3.6432,000RDYDr. Reddy's Laboratories2.7073 of 5 stars$14.46-0.4%$16.95+17.3%-15.0%$12.11B$3.81B21.9027,811News CoveragePositive NewsASNDAscendis Pharma A/S3.4627 of 5 stars$190.37-2.0%$243.36+27.8%+40.3%$11.89B$393.54M-36.891,017News CoveragePositive NewsAnalyst ForecastQGENQIAGEN4.1768 of 5 stars$48.92-1.6%$49.69+1.6%+4.7%$11.06B$1.98B28.905,765News CoverageMRNAModerna4.4071 of 5 stars$25.35-6.5%$42.88+69.2%-68.9%$10.55B$3.06B-3.375,800BBIOBridgeBio Pharma4.0652 of 5 stars$47.29-3.6%$61.35+29.7%+85.9%$9.38B$235.81M-11.56400Positive NewsELANElanco Animal Health2.9083 of 5 stars$17.80-0.6%$17.33-2.6%+18.8%$8.90B$4.48B20.709,000VRNAVerona Pharma PLC American Depositary Share2.3509 of 5 stars$105.62+0.1%$109.00+3.2%+285.4%$8.64B$221.67M-106.6930News CoveragePositive NewsROIVRoivant Sciences3.0387 of 5 stars$11.64-2.3%$16.50+41.8%-2.5%$8.14B$29.05M-16.63860News CoveragePositive NewsAnalyst ForecastGRFSGrifols4.0038 of 5 stars$9.82-3.3%$10.30+4.9%+6.7%$6.99B$7.81B8.3923,822News CoveragePositive News Related Companies and Tools Related Companies VTRS Competitors RDY Competitors ASND Competitors QGEN Competitors MRNA Competitors BBIO Competitors ELAN Competitors VRNA Competitors ROIV Competitors GRFS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACLX) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcellx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcellx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
